Janus Henderson Group PLC Kodiak Sciences Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $67,517 - $124,648	14,037 New	14,037 $87,000
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $2.35 Million - $29.6 Million	-331,067 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$80.85 - $128.49 $348,867 - $554,434	-4,315 Reduced 1.29%	331,067 $28.1 Million
Q3 2021 Nov 16, 2021	BUY	$81.97 - $106.94 $219,761 - $286,706	2,681 Added 0.81%	335,382 $32.2 Million
Q2 2021 Aug 16, 2021	BUY	$77.2 - $126.54 $438,264 - $718,367	5,677 Added 1.74%	332,701 $30.9 Million
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $1.12 Million - $1.67 Million	-10,150 Reduced 3.01%	327,024 $37.1 Million
Q4 2020 Feb 16, 2021	BUY	$60.78 - $154.03 $20.5 Million - $51.9 Million	337,174 New	337,174 $49.5 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.